Pharma BD Deal Intelligence
Astellas Pharma Inc. / Iveric Bio Inc.
2023 · Acquisition/Merger · $5.9B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
75
Worked — the deal delivered on its rationale.
Astellas acquired Iveric Bio for $5.9B for age-related blindness treatments.
Key facts
- Announced May 01, 2023
- Closed Jul 11, 2023
- Deal value $5.9B
- Deal type Acquisition/Merger
- Therapeutic area Ophthalmology
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals